# AbbVie: Phase 1 study terminated, 3 enrolled (Hepatocellular Carcinoma (HCC))

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | AbbVie |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) |
| NCT ID | NCT06487559 |
| Phase | Phase 1 |
| Status | terminated |
| Conditions | Hepatocellular Carcinoma (HCC) |
| Intervention types | drug |
| Target enrollment | 3 |
| Site countries | China |
| Posted | 2024-07-05 |
| Planned start | 2024-09-11 |
| Event | Terminated |
| Event date | 2026-09-18 |
| Last update posted | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06487559). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.